Leucadia Pharmaceuticals has announced the launch and availability of its generic Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL). The FDA-approved generic is therapeutically equivalent to Mallinckrodt Pharmaceuticals’ acetaminophen injection product (Ofirmev).1

Acetaminophen injection is indicated for the management of mild to moderate pain, and management of moderate to severe pain with adjunctive opioid analgesics and reduction of fever.1,2 It is indicated for adult and pediatric patients aged 2 years and older.2

“Acetaminophen Injection is a widely proven therapy for the reduction of pain and fever and demand for expanded options in this market is extremely robust,” said Dr. William Larkins, Chief Executive Officer of Leucadia Pharmaceuticals, in a prepared statement.1

According to Mallinckrodt, the most common adverse effects in patients treated with acetaminophen injection are nausea, vomiting, headache, and insomnia in adults; and nausea, vomiting, constipation, and pruritus in children.2

Serious adverse effects may include hepatic injury, serious skin reactions, allergy, and hypersensitivity.2

  1. Leucadia Pharmaceuticals Launches Acetaminophen Injection [news release]. Carlsbad, CA; December 7, 2020: Leucadia. Accessed December 9, 2020. https://leucadiapharma.com/wp-content/uploads/2020/12/Leucadia-Pharma_Acetaminophen-Injection-Release.pdf
  2. Ofirmev [prescribing information]. Hazelwood, MO: Mallinckrodt Pharmaceuticals; 2020.